Scholarlink

<p><i>Salmonella enterica</i> serovar Typhi (<i>S</i>. Typhi) is a strictly human-restricted Gram-negative pathogen and the causative agent of typhoid fever, a major global health concern. Current treatment relies heavily on antibiotics, however, the rapid emergence of multidrug-resistant strains has severely compromised their efficacy, underscoring the urgent need for alternative therapeutic strategies. The human gut microbiota has emerged as a promising source of antimicrobial molecules, including both peptide and non-peptide compounds. These microbiota-derived agents can inhibit Gram-negative pathogens through diverse mechanisms, such as direct bactericidal activity, modulation of host immune responses, and promotion of colonization resistance. Recent advances in artificial intelligence (AI) and multi-omics technologies have further accelerated the discovery and functional characterization of gut-derived antimicrobials with potent activity against drug-resistant bacteria. In this review, we summarize current understanding of <i>S</i>. Typhi pathogenesis and resistance, highlight the diversity and mechanisms of gut microbiota-derived antimicrobials, and explore their translational potential as innovative therapeutic options for typhoid fever.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential

  • 期刊论文

  • 发表日期：

    2025年8月28日

查看全文
  • Huiya Jin,
  • Hui Sun,
  • Qi Wang,
  • Jing Yang

摘要

Salmonella enterica serovar Typhi (S. Typhi) is a strictly human-restricted Gram-negative pathogen and the causative agent of typhoid fever, a major global health concern. Current treatment relies heavily on antibiotics, however, the rapid emergence of multidrug-resistant strains has severely compromised their efficacy, underscoring the urgent need for alternative therapeutic strategies. The human gut microbiota has emerged as a promising source of antimicrobial molecules, including both peptide and non-peptide compounds. These microbiota-derived agents can inhibit Gram-negative pathogens through diverse mechanisms, such as direct bactericidal activity, modulation of host immune responses, and promotion of colonization resistance. Recent advances in artificial intelligence (AI) and multi-omics technologies have further accelerated the discovery and functional characterization of gut-derived antimicrobials with potent activity against drug-resistant bacteria. In this review, we summarize current understanding of S. Typhi pathogenesis and resistance, highlight the diversity and mechanisms of gut microbiota-derived antimicrobials, and explore their translational potential as innovative therapeutic options for typhoid fever.